Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer

BACKGROUND: Bevacizumab prolongs progression-free survival (PFS) in patients with metastatic colorectal cancer. We analysed the protein expression levels of vascular endothelial growth factor (VEGF) ligands and receptors to determine their prognostic and predictive effects. METHODS: We graded expres...

Descripción completa

Detalles Bibliográficos
Autores principales: Weickhardt, A J, Williams, D S, Lee, C K, Chionh, F, Simes, J, Murone, C, Wilson, K, Parry, M M, Asadi, K, Scott, A M, Punt, C J A, Nagtegaal, I D, Price, T J, Mariadason, J M, Tebbutt, N C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4647541/
https://www.ncbi.nlm.nih.gov/pubmed/26125443
http://dx.doi.org/10.1038/bjc.2015.209

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4647541/
https://www.ncbi.nlm.nih.gov/pubmed/26125443
http://dx.doi.org/10.1038/bjc.2015.209

Ejemplares similares